Loading
A phase 3 trial of Ibandronic acid and Zoledronic acid in Breast cancer and Metastatic cancer, run by Wales Cancer Trials Unit, with a status the registry has not verified recently.
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer is a phase 3 interventional study registered as NCT00326820 by Wales Cancer Trials Unit, with 1404 participants planned, started 2006-01 and due to reach its primary completion in 2012-12. Interventions recorded: ibandronate sodium, zoledronic acid, Zolendronic Acid. Conditions recorded: Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer.
Linked to the drug Ibandronic acid because the registry names it among its interventions and Breast cancer and Metastatic cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ibandronic acid, Zoledronic acid and the tag pipeline.
Shares Ibandronic acid, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zoledronic acid, Breast cancer (all types) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/